Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 May 2;373(9674):1550-61.
doi: 10.1016/S0140-6736(09)60237-3. Epub 2009 Mar 11.

Graft-versus-host disease

James L M Ferrara  1 , John E Levine, Pavan Reddy, Ernst Holler
Affiliations
Review

Graft-versus-host disease

James L M Ferrara et al. Lancet. .

Abstract

Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk haematological malignant disorders and other life-threatening haematological and genetic diseases. The main complication of HCT is graft-versus-host disease (GVHD), an immunological disorder that affects many organ systems, including the gastrointestinal tract, liver, skin, and lungs. The number of patients with this complication continues to grow, and many return home from transplant centres after HCT requiring continued treatment with immunosuppressive drugs that increases their risks for serious infections and other complications. In this Seminar, we review our understanding of the risk factors and causes of GHVD, the cellular and cytokine networks implicated in its pathophysiology, and current strategies to prevent and treat the disease. We also summarise supportive-care measures that are essential for management of this medically fragile population.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Acute GVHD of the skin (Grade I). Photograph courtesy of J. Levine, M.D.
Figure 2
Figure 2. Chronic GVHD: Lichenoid changes of the buccal mucosa. Photograph courtesy of J. P. Guadagrini, D.D.S.
Figure 3
Figure 3. GVHD Pathophysiology
In Phase I, the recipient conditioning regimen damages host tissues and causes release of inflammatory cytokines such as TNFα, IL-1 and IL-6. Increased levels of these cytokines leads to activation of host antigen presenting cells (APCs). In Phase II, host APCs activate mature donor cells. The subsequent proliferation and differentiation of these activated T cells produces additional effectors that mediate the tissue damage, including Cytotoxic T Lymphocytes, Natural Killer (NK) cells, TNFα and IL-1. Lipopolysaccharide (LPS) that has leaked through the damaged intestinal mucosa triggers additional TNFα production. TNFα can damage tissue directly by inducing necrosis and apoptosis in the skin and GI tract through either TNF receptors or the Fas pathway. TNFα plays a direct role in intestinal GVHD damage which further amplifies damage in the skin, liver and lung in a “cytokine storm.”
See this image and copyright information in PMC

References

    1. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389. - PubMed
    1. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–170. - PubMed
    1. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966-67;62:21–78. - PubMed
    1. Korngold R, Sprent J. Purified T cell subsets and lethal graft-versus-host disease in mice. In: Gale RP, Champlin R, editors. Progress in Bone Marrow Transplantation. Alan R. Liss, Inc.; New York: 1987. pp. 213–218.
    1. Kernan NA, Collins NH, Juliano LL, Cartagena TT, Dupont BB, OReilly RJ. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68:770–773. - PubMed

Publication types

MeSH terms